Apricitabine: A novel deoxycytidine analogue nucleoside reverse transcriptase inhibitor for the treatment of nucleoside-resistant HIV infection

Antiviral Chemistry and Chemotherapy

Volumn 18, Issue 2, 2007, Pages 61-70

  Wainberg, Mark A ^a   Cahn, Pedro ^b   Bethell, Richard C ^c,d   Sawyer, James ^e   Cox, Susan ^f  

^a MCGILL UNIVERSITY   (Canada)

^b FUNDACIÓN HUÉSPED   (Argentina)

^c Shire Canada   (Canada)

^d Boehringer lngelheim Canada Ltd   (Canada)

^e Prism Ideas   (United Kingdom)

^f Avexa Ltd   (Australia)

Author keywords

Apricitabine; ATC; AVX754; HIV 1; Reverse transcriptase inhibitors

Indexed keywords

ABACAVIR; APRICITABINE; AVX 754; BCH 10618; DIDANOSINE; EMTRICITABINE; LAMIVUDINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; SPD 754; STAVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

BONE MARROW TOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG STRUCTURE; DRUG TOLERABILITY; FATTY LIVER; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERPIGMENTATION; IN VITRO STUDY; LACTIC ACIDOSIS; LIPODYSTROPHY; MITOCHONDRIAL MYOPATHY; MONOTHERAPY; NOSE CONGESTION; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SINGLE DRUG DOSE; VIRUS LOAD;

EID: 34249290103     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632020701800201     Document Type: Review

References (43)

1. Ait-Khaled M, Stone C, Amphlett G, Clotet B, Staszewski S, Katlama C, Tisdale M & CNA3002 International Study Team (2002) M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine. AIDS 16:1686-1689.
2. Anderson PL, Kakuda TN & Lichtenstein KA (2004) The cellular pharmacology of nucleoside- and nucleotide-analogue reverse-transcriptase inhibitors and its relationship to clinical toxicities. Clinical Infectious Diseases 38:743-753.
3. Antinori A, Trotta MP, Nasta P, Bini T, Bonora S, Castagna A, Zaccarelli M, Quirino T, Landonio S, Merli S, Tozzi V, Di Perri G, Andreoni M, Perno CF & Carosi G (2006) Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/ tenofovir in highly active antiretroviral therapy experienced patients. Antiviral Therapy 11:233-243.
4. Back DJ, Burger DM, Flexner CW & Gerber JG (2005) The pharmacology of antiretroviral nucleoside and nucleotide reverse transcriptase inhibitors: implications for once-daily dosing. Journal of Acquired Immune Deficiency Syndromes 39 Suppl 1:S1-S23
5. Bethell RC, Lie YS & Parkin NT (2005) In vitro activity of SPD754 (ATC), a new deoxycytidine nucleoside reverse transcriptase inhibitor (NRTI), against 215 HIV-1 isolates resistant to other NRTIs. Antiviral Chemistry & Chemotherapy 16:295-302.
6. Boucher S, Recordon-Pinson P, Ragnaud JM, Dupon M, Fleury H & Masquelier B (2006) HIV-1 reverse transcriptase (RT) genotypic patterns and treatment characteristics associated with the K65R RT mutation. HIV Medicine 7:294-298.
7. Cahn P, Cassetti I, Wood R, Phanuphak P, Shiveley L, Bethell RC & Sawyer J (2006) Efficacy and tolerability of 10-day monotherapy with apricitabine in antiretroviral-naive, HIV-infected patients. AIDS 20:1261-1268.
8. Castagna A, Danise A, Menzo S, Galli L, Gianotti N, Carini E, Boeri E, Galli A, Cernuschi M, Hasson H, Clementi M & Lazzarin A (2006) Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study). AIDS 2006; 20:795-803.
9. de Muys JM, Gourdeau H, Nguyen-Ba N, Taylor DL, Ahmed PS, Mansour T, Locas C, Richard N, Wainberg MA & Rando RF. (1999) Anti-human immunodeficiency virus type 1 activity, intracellular metabolism and pharmacokinetics evaluation of 2′-deoxy-3′-oxa-4′- thiocytidine. Antimicrobial Agents and Chemotherapy 43:1835-1844.
10. Deeks SG (2004) Treatment of antiretroviral-drug-resistant HIV-1 infection. Lancet 362:2002-2011.
11. Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents, Oct 10, 2006 [cited 5 Apr 2007]. Available at http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL. pdf.
12. Diallo K, Götte D & Wainberg MA (2003) Molecular impact of the M184V mutation in human immunodeficiency virus type 1 reverse transcriptase. Antimicrobial Agents and Chemotherapy 47:3377-3383.
13. Dunkle LM, Gathe JC, Pedevillano DE, Robison HG, Rice WG, Pottage JC Jr and the ACH-006 Study Team (2003) Elvucitabine: potent antiviral activity demonstrated in multi-drug resistant HIV infection. Antiviral Therapy 8:S5.
14. Emtriva™ Prescribing Information. Gilead Sciences, Inc. Sept 2005.
15. Frankel FA, Coutsinos D, Xu H & Wainberg MA (2007) Kinetics of inhibition of HIV type 1 reverse transcriptase-bearing NRTI-associated mutations by apricitabine triphosphate. Antiviral Chemistry and Chemotherapy 18:93-101.
16. Gallant JE (2005) Approach to the treatment-experienced patient. Current HIV/AIDS Report. 2: 83-89.
17. Gazzard B, on behalf of the British HIV Association (2005) British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Medicine 6 Suppl 2:1-61.
18. Gu Z, Allard B, de Muys JM, Lippens J, Rando RF, Nguyen-Ba N, Ren C, McKenna P, Taylor DL & Bethell RC (2006) In vitro antiretroviral activity and in vitro toxicity profile of SPD754 (ATC), a new deoxycytidine nucleoside reverse transcriptase inhibitor for treatment of human immunodeficiency virus infection. Antimicrobial Agents and Chemotherapy 50:625-631.
19. Gu Z, Nguyen-Ba N, Ren C, De Muys JM, Allard B, Wainberg MA, McKenna P, Taylor DL & Bethell RC (2001) BCH-10618, a new heterosubstituted nucleoside analogue against HIV-1 infection. Antiviral Therapy 6 Suppl 1:8.
20. Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, Thompson MA, Carpenter CC, Fischi MA, Gazzard BG, Gatell JM, Hirsch MS, Katzenstein DA, Richman DD, Vella S, Yeni PG, Volberding PA & International AIDS Society-USA panel. (2006) Treatment for adult HIV infection. 2006 recommendations of the International AIDS Society-USA Panel. Journal of the American Medical Association 296:827-843.
21. Holdich L, Shiveley L & Sawyer J (2006) Pharmacokinetics of apricitabine, a novel deoxycytidine analogue reverse transcriptase inhibitor, in healthy volunteers. Clinical Drug Investigation 26:279-286.
22. Holdich T, Shiveley L & Sawyer J (2007) Effect of lamivudine on the plasma and cellular pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in healthy volunteers. Antimicrobial Agents and Chemotherapy: doi:10.1128/AAC.01013-06 [Epub ahead of print]
23. Kagan RM, Merigan TC, Winters MA & Heseltine PN (2004) Increasing prevalence of HIV-I reverse transcriptase mutation K65R correlates with tenofovir utilization. Antiviral Therapy 9:827-828.
24. Kakuda TN (2000) Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clinical Therapeutics 22:685-708.
25. Kuritzkes DR, Quinn JB, Benoit SL, Shugarts DL, Griffin A, Bakhtiari M, Poticha D, Eron JJ, Fallon MA & Rubin M (1996) Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients. AIDS 10:975-981.
26. Lanier ER, Givens N, Stone C, Griffin P, Gibb D, Walker S, Tisdale M, Irlbeck D, Underwood M, St Clair M & Ait-Khaled M. (2004) Effect of concurrent zidovudine use on the resistance pathway selected by abacavir-containing regimens. HIV Medicine 5:394-399.
27. Louie M, Hogan C, Hurley A, Simon V, Chung C & Padte N (2003) Determining the antiviral activity of tenofovir disoproxil fumarate in treatment naïve chronically infected individuals. AIDS 17:1151-1156.
28. Maguire M, Gartland M, Moore S, Hill A, Tisdale M, Harrigan R & Kleim JP (2000) Absence of zidovudine resistance in antiretroviral-naive patients following zidovudine/lamivudine/protease inhibitor combination therapy: virological evaluation of the AVANTI 2 and AVANTI 3 studies. AIDS 14:1195-1201.
29. Margot NA, Isaacson E, McGowan I, Cheng A & Miller MD (2003) Extended treatment with tenofovir disoproxil fumarate in treatment-experienced HIV-1-infected patients: genotypic, phenotypic, and rebound analyses. Journal of Acquired Immune Deficiency Syndrome 33:15-21.
30. Miller MD (2004) K65R, TAMs and tenofovir. AIDS Review 6:22-33.
31. Nakatani-Freshwater T, Babayeva M, Dontabhaktuni A & Taft DR (2006). Effects of trimethoprim on the clearance of apricitabine, a deoxycytidine analog reverse transcriptase inhibitor, and lamivudine in the isolated perfused rat kidney. Journal of Pharmacology and Experimental Therapeutics. 319:941-947.
32. Parikh UM, Bacheler L, Koontz D & Mellors JW (2006) The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations. Journal of Virology 80:4971-4977.
33. Petrella M, Oliveira M, Moisi D, Detorio M, Brenner BG & Wainberg MA (2004) Differential maintenance of the M184V substitution in the reverse transcriptase of human immunodeficiency virus type 1 by various nucleoside antiretroviral agents in tissue culture. Antimicrobial Agents and Chemotherapy 48:4189-4194.
34. Ray AS (2005) Intracellular interactions between nucleos(t)ide inhibitors of HIV reverse transcriptase. AIDS Review 7:113-125.
35. Rousseau FS (2003) Prospective randomized trial of emtricitabine versus lamivudine short-term monotherapy in human immunodeficiency virus-infected patients. Journal Infectious Diseases 188:1652-1658.
36. Tamalet C, Fantini J, Tourres C & Yahi N (2003) Resistance of HIV-1 to multiple antiretroviral drugs in France: a 6-year survey (1997-2002) based on an analysis of over 7000 genotypes. AIDS 17:2383-2388.
37. Taylor DL, Ahmed PS, Tyms AS, Wood LJ, Kelly LA, Chambers P, Clarke J, Bedard J, Bowlin TL & Rando RF (2000) Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 ((±)-2′-deoxy-3′-oxa-4′-thiocytidine, dOTC). Antiviral Chemistry and Chemotherapy 11:291-301.
38. Wainberg MA, Sawyer JP, Montaner JS, Murphy RL, Kuritzkes DR & Raffi F (2005a) Challenges for the clinical development of new nucleoside reverse transcriptase inhibitors for HIV infection. Antiviral Therapy 10:13-28.
39. Wainberg MA, Brenner BG & Turner D (2005b) Changing patterns in the selection of viral mutations among patients receiving nucleoside and nucleotide drug combinations directed against human immunodeficiency virus type 1 reverse transcriptase. Antimicrobial Agents and Chemotherapy 49:1671-1678.
40. Wainberg MA, Miller MD, Quan Y, Salomon H, Mulato AS, Lamy PD, Margot NA, Anton KE & Cherrington JM (1999) In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antiviral Therapy 4:87-94.
41. Whitcomb JM, Parkin NT, Chappey C, Hellmann NS & Petropoulos CJ (2003) Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates. Journal of Infectious Diseases 188:992-1000.
42. Winston A, Pozniak A, Mandalia S, Gazzard B, Pillay D & Nelson M (2004) Which nucleoside and nucleotide backbone combinations select for the K65R mutation in HIV-1 reverse transcriptase. AIDS 18:949-957.
43. Wood R, Trope B, Van Leeuwen R, Martin DE & Proulx L (1999) Potent antiretroviral activity of dOTC (BCH-10652) in HIV-1-infected patients: initial results from a phase I/II clinical trial. In Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology. Abstract 503